Vita 34 AG Stock
Price
Target price
€5.95
€5.95
-0.830%
-
-0.830%
€7.00
22.12.25 / Tradegate
WKN: A0BL84 / Name: Vita 34 / Stock / Healthcare Providers & Services / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Vita 34 AG Stock
The price for the Vita 34 AG stock decreased slightly today. Compared to yesterday there is a change of €0.000 (-0.830%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Vita 34 AG stock is not clear.
With a target price of 7 € there is a slightly positive potential of 17.65% for Vita 34 AG compared to the current price of 5.95 €.
So far the community has only identified positive things for Vita 34 AG stock. The most positive votes were given for criterium "Market Position".
Pros and Cons of Vita 34 AG in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Vita 34 AG vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vita 34 AG | -0.830% | -7.031% | 11.215% | 44.417% | 44.417% | -26.724% | -51.626% |
| Mediclin AG | 0.560% | -2.162% | 5.233% | 50.833% | 52.101% | 7.101% | -3.723% |
| M1 Kliniken AG | -0.230% | 2.301% | 11.824% | 12.889% | 6.787% | 114.217% | 102.506% |
| Addus Homecare Corp. | -0.530% | -2.083% | 0.000% | -22.951% | -21.667% | -1.053% | 2.732% |
News
EQS-News: FamiCord AG accelerates profitable growth in the third quarter of 2025 and further strengthens quality and visibility of revenues
EQS-News: FamiCord AG accelerates profitable growth in the third quarter of 2025 and further strengthens quality and visibility of revenues
EQS-Adhoc: FamiCord AG: Polski Bank Komórek Macierzystych sp. z o. o. is to acquire 100 % in stem cell bank “nOvum” spółka z ograniczoną odpowiedzialnością, Warsaw, Poland
EQS-Adhoc: FamiCord AG: Polski Bank Komórek Macierzystych sp. z o. o. is to acquire 100 % in stem cell bank “nOvum” spółka z ograniczoną odpowiedzialnością, Warsaw, Poland
EQS-News: FamiCord AG significantly increases revenue and earnings in the first half of 2025 and shifts focus even more strongly to core business in the future
EQS-News: FamiCord AG significantly increases revenue and earnings in the first half of 2025 and shifts focus even more strongly to core business in the future